Hims & Hers drafts Super Bowl star Rob Gronkowski to drive men’s health awarenessnews2021-09-10T13:28:29+00:00September 10th, 2021|Fierce Pharma|
Fierce Pharma Asia—Takeda’s AbbVie drug supply lawsuit, Novavax’ COVID vaccine deal; Juno, WuXi’s CAR-T nodnews2021-09-10T09:53:37+00:00September 10th, 2021|Fierce Pharma|
Despite mixed phase 3 showing, Apellis hopes to push eye disorder drug past FDA’s finish linenews2021-09-09T19:34:20+00:00September 9th, 2021|Fierce Pharma|
Biogen CEO blames Aduhelm’s rocky launch on ‘too much confusion, misinformation and controversy’news2021-09-09T18:20:56+00:00September 9th, 2021|Fierce Pharma|
Tossing same-old pharma marketing, agency veteran turns to Clubhouse and digital health democracy for inspirationnews2021-09-09T17:06:50+00:00September 9th, 2021|Fierce Pharma|
Acorda slashes jobs again as generics hamper sales of MS drugnews2021-09-09T15:47:51+00:00September 9th, 2021|Fierce Pharma|
Perrigo dishes out $2.1B for HRA Pharma, a big step on its quest to become self-care heavyweightnews2021-09-09T15:37:07+00:00September 9th, 2021|Fierce Pharma|
WCLC: Jazz charts new path for small cell lung cancer drug Zepzelca after late-stage flopnews2021-09-09T14:50:16+00:00September 9th, 2021|Fierce Pharma|
No dice: Court tells AbbVie it can’t force Takeda to supply a drug that’s in shortage worldwidenews2021-09-09T14:33:36+00:00September 9th, 2021|Fierce Pharma|
AstraZeneca’s COVID-19 shot joins the list of vaccines flagged for rare Guillain-Barre syndromenews2021-09-09T13:43:23+00:00September 9th, 2021|Fierce Pharma|
